Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-assisted Immunoinflammatory Subtyping-Directed Precision Treatment in Acute Aortic Dissection
NCT07382375Not yet recruiting
- Sponsor
- Nanjing Medical University
- Start
- Dec 2027
- Primary completion
- Dec 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial of ulinastatin and thymosin alpha 1 in aortic dissection (2 arms), sponsored by Nanjing Medical University. Primary endpoint: Sequential Organ Failure Assessment at 7 days. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
ulinastatinthymosin alpha 1
03
Conditions
aortic dissection
Beyond the preview
Go deeper on NCT07382375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07382375.